DB
RXDX

Dmitry Balyasny’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Dmitry Balyasny’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-262,702
Closed -$15.5M – 3379
2022
Q3 		$15.5M Buy
262,702
+21,116
+9% +$966K 0.05% 515
2022
Q2 		$6.82M Buy
+241,586
New +$7M 0.02% 811

Other funds holding RXDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Dmitry Balyasny's RXDX Position: Q4 2022 in Review

Dmitry Balyasny sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022, closing a stake of 262,702 shares — an estimated $15.5M sold.

Dmitry Balyasny first reported a position in RXDX in Q2 2022 and held it in 2 quarters. The position peaked at $15.5M in Q3 2022. 221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

  • Dmitry Balyasny reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 262,702 Prometheus Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $15.5M.
  • Dmitry Balyasny first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Prometheus Biosciences, Inc. Common Stock position peaked at $15.5M in Q3 2022.
  • 221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.